Avenciguat
- Generic Name
- Avenciguat
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
- Conditions
- Liver DiseasesHypertension, Portal
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT05282121
- Locations
- π«π·
HOP Beaujon, Clichy, France
π«π·HOP Rangueil, Toulouse, France
π©πͺMedizinische Hochschule Hannover, Hannover, Germany
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
- Conditions
- Diabetic Nephropathies
- Interventions
- Drug: Placebo matching BI 685509
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 243
- Registration Number
- NCT04750577
- Locations
- ππ°
Prince of Wales Hospital, Hong Kong, Hong Kong
ππ°Tung Wah Hospital, Hong Kong, Hong Kong
π²πΎUniversiti Sains Malaysia Hospital, Kelantan, Malaysia
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 261
- Registration Number
- NCT04736628
- Locations
- πΊπΈ
Research by Design, LLC, Chicago, Illinois, United States
πΊπΈHomestead Associates in Research, Miami, Florida, United States
πΊπΈNevada Kidney Disease and Hypertension Centers, PLLC, Las Vegas, Nevada, United States
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT03842761
- Locations
- πΊπΈ
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03259464
- Locations
- π―π΅
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 75
- Registration Number
- NCT03165227
- Locations
- πΊπΈ
Indago Research and Health Center, Hialeah, Florida, United States
πΊπΈResearch by Design, LLC, Chicago, Illinois, United States
πΊπΈHouston Clinical Research Associates, Houston, Texas, United States
Safety and Tolerability of BI 685509 in Healthy Subjects
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT03116906
- Locations
- π©πͺ
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Investigation of Single Rising Doses of BI 685509
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02694354
- Locations
- π©πͺ
1366.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.